VCP and cancer: In addition, as many cancers have dysregulated DNA repair pathways, inactivation of the p97–ATX3 complex might be a promising strategy to induce synthetic lethality in those cancers where the HR pathway is inactivated, such as BRCA2‐deficient cancers.